In a groundbreaking move, President Trump has forged agreements with major pharmaceutical companies to significantly lower drug prices for Americans, ensuring access to affordable medications for chronic conditions.
In an 18-minute speech, Trump made numerous claims about the economy, immigration, and military. While some were accurate, many were misleading. NBC News fact-checks eight of the key assertions.
In a bold declaration, President Trump claims drug prices have plummeted by 1,500%, sparking controversy and skepticism. As he positions himself as the 'affordability president,' critics question the validity of his statements.
Eli Lilly & Co. and Novo Nordisk A/S have struck a deal with the Trump administration to lower prices for their popular weight-loss drugs, Zepbound and Wegovy, while gaining tariff relief and expanding Medicare access. This agreement aims to increase availability for older Americans.
In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
In a groundbreaking move, President Trump announces deals with Eli Lilly and Novo Nordisk to reduce obesity drug prices, making treatments more accessible for millions of Americans. Medicare coverage for GLP-1 drugs starts in 2026, changing the landscape of obesity treatment.
In a major move against high prescription costs, AstraZeneca has agreed to sell its drugs at a discount through Medicaid, marking a significant win for the Trump administration's healthcare initiative.
AstraZeneca partners with the Trump administration to offer drastically lower drug prices through Medicaid and the upcoming TrumpRx platform, aiming to make medications more accessible to consumers.
In a significant announcement, President Trump is set to reveal a new drug pricing deal with AstraZeneca, following a similar agreement with Pfizer. This move aims to lower U.S. drug prices and pressure major drugmakers to bring manufacturing back to America. Will it lead to real savings for taxpayers?
In a bold move to reduce U.S. prescription drug prices, AstraZeneca and Pfizer have struck deals with the White House, promising significant discounts for patients. This comes amid rising pressure from President Trump on drugmakers to lower costs or face hefty tariffs. Will these changes truly benefit American patients?